Publication & Citation Trends
Publications
17 total
Abstract 450: JZY-2233: An antigen-targeted CBP/p300 degrader-antibody conjugate for advanced prostate cancer therapy.
Cited by 0
OpenAlex
Abstract 5289: Native domain-interaction rewiring collapses the AR neo-enhanceosome in prostate cancer
Cited by 0
OpenAlex
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition PDF
Cited by 7
OpenAlex
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma PDF
Cited by 6
OpenAlex
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13 PDF
Cited by 25
OpenAlex
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition PDF
Cited by 18
OpenAlex
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader PDF
Cited by 15
OpenAlex
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality PDF
Cited by 1
OpenAlex
Research Topics
Protein Degradation and Inhibitors
(6)
Advanced Breast Cancer Therapies
(5)
Prostate Cancer Treatment and Research
(4)
Cancer-related Molecular Pathways
(4)
HER2/EGFR in Cancer Research
(3)
Affiliations
RELX Group (Netherlands)
Jinan University
Chinese Academy of Sciences
University of Michigan
Temple College